INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 51 filers reported holding INOZYME PHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,977,294 | -11.7% | 4,280,308 | +17.1% | 1.13% | -15.0% |
| Q2 2023 | $20,360,066 | -2.8% | 3,655,308 | 0.0% | 1.33% | -0.4% |
| Q1 2023 | $20,944,915 | +445.7% | 3,655,308 | 0.0% | 1.34% | +487.7% |
| Q4 2022 | $3,838,073 | -60.8% | 3,655,308 | 0.0% | 0.23% | -60.0% |
| Q3 2022 | $9,796,000 | -43.8% | 3,655,308 | 0.0% | 0.57% | -60.7% |
| Q2 2022 | $17,436,000 | +110.2% | 3,655,308 | +80.2% | 1.45% | +130.5% |
| Q1 2022 | $8,296,000 | -40.0% | 2,028,308 | 0.0% | 0.63% | -22.0% |
| Q4 2021 | $13,833,000 | -41.2% | 2,028,308 | 0.0% | 0.81% | -42.0% |
| Q3 2021 | $23,508,000 | -32.0% | 2,028,308 | 0.0% | 1.39% | -30.1% |
| Q2 2021 | $34,562,000 | -13.9% | 2,028,308 | 0.0% | 1.99% | -17.5% |
| Q1 2021 | $40,160,000 | -4.1% | 2,028,308 | 0.0% | 2.41% | -3.1% |
| Q4 2020 | $41,864,000 | -21.5% | 2,028,308 | 0.0% | 2.49% | -37.0% |
| Q3 2020 | $53,324,000 | – | 2,028,308 | – | 3.95% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $27,113,000 | 10.69% |
| Burrage Capital Management LLC | 242,517 | $4,132,000 | 4.14% |
| CHI Advisors LLC | 927,264 | $15,801,000 | 3.68% |
| Sofinnova Investments, Inc. | 2,028,308 | $34,562,000 | 1.99% |
| Novo Holdings A/S | 1,867,706 | $31,826,000 | 1.41% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,178,985 | $37,130,000 | 0.66% |
| RA Capital Management | 2,003,653 | $34,142,000 | 0.55% |
| NEA Management Company, LLC | 2,444,379 | $41,652,000 | 0.54% |
| Rock Springs Capital Management LP | 840,272 | $14,318,000 | 0.28% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 365,172 | $6,223,000 | 0.09% |